Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020

Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand1

Patpong Rongkard, Barbara Kronsteiner, Viriya Hantrakun, Kemajittra Jenjaroen, Manutsanun Sumonwiriya, Panjaporn Chaichana, Suchintana Chumseng, Narisara Chantratita, Vanaporn Wuthiekanun, Helen A. Fletcher, Prapit Teparrukkul, Direk Limmathurotsakul, Nicholas P.J. Day, and Susanna J. DunachieComments to Author 
Author affiliations: University of Oxford, Oxford, UK (P. Rongkard, B. Kronsteiner, N.P.J. Day, S.J. Dunachie); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (P. Rongkard, V. Hantrakun, K. Jenjaroen, M. Sumonwiriya, P. Chaichana, S. Chumseng, N. Chantratita, V. Wuthiekanun, D. Limmathurotsakul, N.P.J. Day, S.J. Dunachie); Mahidol University, Bangkok (N. Chantratita, D. Limmathurotsakul); London School of Hygiene and Tropical Medicine, London, UK (H.A. Fletcher); Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (P. Teparrukkul)

Main Article

Table 1

Proportions of samples from 4 patient and control cohorts used to evaluate immune responses to melioidosis, Thailand*

Cohort No. (%) samples by assay
Melioidosis, n = 99 73 (74) 82 (83) 13 (13)
Healthy household contacts, n = 96 35 (36) 93 (97) 8 (8)
Diabetes control, n = 98 54 (55) 95 (97) NA
Other gram-negative bacterial infections, n = 48 10 (20) 42 (88) NA

*IFN-γ ELISpot, interferon-γ enzyme-linked immunospot assay; IHA, indirect hemagglutination assay; NA, not available; WBA, whole-blood stimulation assay.

Main Article

1Preliminary results from this study were presented at the European Melioidosis Congress, March 19–21, 2018, Oxford, UK.

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.